FIELD: medicine.
SUBSTANCE: invention concerns biotechnology. The methods of angiogenesis depression or inhibition at an individual with the pathological condition bound to an angiogenesis, providing administration of antagonist EGFL7 to an individual, capable interfering migration of endothelial cells induced by EGFL7, thereby reducing or inhibiting an angiogenesis at an individual is described. The invention can be used for regulation of the processes involved in an angiogenesis.
EFFECT: development of an effective way of depression or inhibition of an angiogenesis at an individual with the pathological condition bound to angiogenesis.
13 cl, 38 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INHIBITING ANGIOGENESIS BY EGFL8 ANTAGONISTS | 2009 |
|
RU2486200C2 |
| EGFL7 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2007 |
|
RU2415870C2 |
| METHODS OF DIAGNOSIS AND COMPOSITION FOR CANCER TREATMENT | 2013 |
|
RU2666627C2 |
| ANGIOPOIETIC ANGIOPOIETIN-LIKE PROTEIN 4 INHIBITORS, IN COMBINATIONS AND APPLICATION | 2005 |
|
RU2392966C2 |
| BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS | 2013 |
|
RU2659173C2 |
| INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS | 2010 |
|
RU2567803C2 |
| ANGIOGENESIS INHIBITION | 2008 |
|
RU2471498C2 |
| ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION | 2007 |
|
RU2559532C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| COMBINED THERAPY WITH USING ALPHA5BETA1 ANTAGONISTS | 2007 |
|
RU2465282C2 |
